# US 2016/0355553 A1 · Influenza virus vaccines and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0355553 A1
- Document ID: US20160355553A1
- Status: Published application
- Kind: A1
- Application number: 15/243,738
- Filed: 2016-08-22
- Published: 2016-12-08
- Earliest claimed: 2011-11-28
- Assignees: Janssen Vaccines & Prevention B.V.
- Applicants: Janssen Vaccines & Prevention B.V.
- Inventors: Jan Willem Meijberg; Antonietta Impagliazzo; Ronald Vogels; Robert H.E. Friesen; Philippe Alard; Stefan Loverix; Katarina Radosevic
- Web page: https://patentgrep.com/patent/US20160355553A1

## CPC

- C07K 14/005: from viruses
- A61K 39/12: Viral antigens
- A61K 39/145: Orthomyxoviridae, e.g. influenza virus
- A61P 31/14: for RNA viruses
- A61P 31/16: for influenza or rhinoviruses
- C07K 16/108: Orthomyxoviridae (F), e.g. influenza virus
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2039/5258: {Virus-like particles}
- A61K 2039/55522: {Cytokines; Lymphokines; Interferons}
- A61K 2039/575: {humoral response}
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2319/21: containing a His-tag
- C07K 2319/35: containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
- C07K 2319/40: containing a tag for immunodetection, or an epitope for immunisation
- C07K 2319/50: containing protease site
- C07K 2319/73: containing coiled-coiled motif (leucine zippers)
- C12N 2760/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/16151: Methods of production or purification of viral material
- C12N 2760/16171: Demonstrated in vivo effect
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure provides influenza hemagglutinin stem domain polypeptides comprising (a) an influenza hemagglutinin HA1 domain that comprises an HA1 N-terminal stem segment, covalently linked by a linking sequence of 0-50 amino acid residues to an HA1 C-terminal stem segment, and (b) an influenza hemagglutinin HA2 domain, wherein on or more amino acids in the HA2 domain have been mutated. Also provided are nucleic acids encoding the polypeptides, compositions comprising the polypeptides and/or nucleic acid molecules, as well as methods of their use, in particular in the detection, prevention and/or treatment of influenza.

## Claims

### Claim 1

An influenza hemagglutinin stem domain polypeptide comprising:
an influenza hemagglutinin HA1 domain comprising an HA1 N-terminal stem segment, covalently linked by a linking sequence of 0-50 amino acid residues to an HA1 C-terminal stem segment, and
an influenza hemagglutinin HA2 domain,
wherein the hemagglutinin stem domain polypeptide is resistant to protease cleavage at a junction between HA1 and HA2,
wherein one or more amino acids in the peptide connecting the A helix and the helix CD of HA2 are mutated as compared to a wild-type influenza HA2 domain, and
wherein the HA1 domain and HA2 domain are derived from an influenza A virus subtype selected from the group consisting of H1, H5, and H3.

### Claim 2 (depends on 1)

The influenza hemagglutinin stem domain polypeptide of claim 1, wherein the influenza hemagglutinin stem domain polypeptide does not comprise a full-length HA1 domain.

### Claim 3 (depends on 1)

The influenza hemagglutinin stem domain polypeptide of claim 1, wherein the influenza hemagglutinin stem domain polypeptide is glycosylated.

### Claim 4 (depends on 1)

The influenza hemagglutinin stem domain polypeptide of claim 1, comprising:
an HA1 N-terminal segment comprising the amino acids 1-x of HA1
covalently linked by a linking sequence of 0-50 amino acid residues to an HA1 C-terminal stem segment comprising the amino acids y-end of HA1 and
an influenza hemagglutinin HA2 domain.

### Claim 5 (depends on 1)

The influenza hemagglutinin stem domain polypeptide of claim 1, comprising:
an influenza hemagglutinin HA1 and/or HA2 domain based upon influenza hemagglutinin from an influenza A virus comprising HA of the H1 subtype, and
wherein x=any amino acid between 46 and 60 and y=any amino acid between 290 and 325.

### Claim 6 (depends on 5)

The influenza hemagglutinin stem domain polypeptide of claim 5, comprising:
an influenza hemagglutinin HA1 and/or HA2 domain based upon influenza hemagglutinin from an influenza A virus comprising HA of the H1 subtype selected from the group consisting of A/Solomon Islands/6/2003, A/Brisbane/59/2007, A/New Caledonia/20/1999, A/California/07/2009, A/swine/Hubei/S1/2009, A/swine/Haseluenne/IDT2617/2003, A/NewYork/8/2006, A/SolomonIslands/3/2006, A/NewYork/146/2000, A/NewYork/653/1996, A/Beijing/262/1995, A/Texas/36/1991, A/Singapore/6/1986, A/Chile/1/1983, A/Baylor/11515/1982, A/Brazil/11/1978, A/USSR/90/1977, A/NewJersey/8/1976, A/Denver/1957, A/Albany/4835/1948, A/FortMonmouth/1/1947, A/Cameron/1946, A/Weiss/1943, A/Iowa/1943, A/Bellamy/1942, A/PuertoRico/8/1934, A/WSN/1933, and A/SouthCarolina/1/1918.

### Claim 7 (depends on 1)

The influenza hemagglutinin stem domain polypeptide of claim 1, comprising:
an influenza hemagglutinin HA1. and/or HA2 domain based upon influenza hemagglutinin from an influenza A virus comprising HA of the H3 subtype,
wherein x=any amino acid between 56 and 69, and
wherein and y=any amino acid between 292 and 325.

### Claim 8 (depends on 1)

The influenza hemagglutinin stem domain polypeptide of claim 1, wherein the C-terminal amino acid residue of the HA1 C-terminal stem segment is any amino acid other than arginine (R),or lysine (K).

### Claim 9 (depends on 1)

The influenza hemagglutinin stem domain polypeptide of claim 1, comprising:
at least one or further mutations in the HA1 domain and/or the HA2 domain.

### Claim 10 (depends on 1)

The influenza hemagglutinin stem domain polypeptide of claim 1, wherein the influenza hemagglutinin stem domain polypeptide comprises at least one disulfide bridge.

### Claim 11 (depends on 1)

The influenza hemagglutinin stem domain polypeptide of claim 1, wherein the influenza hemagglutinin stem domain polypeptide does not comprise the signal sequence.

### Claim 12 (depends on 11)

The influenza hemagglutinin stem domain polypeptide of claim 11, comprising:
an HA1 N-terminal segment comprising amino acids p-x of HA1, covalently linked by a linking sequence of 0-50 amino acid residues to an HA1 C-terminal stem segment comprising the amino acids y-end of HA1, and
an influenza hemagglutinin HA2 domain, wherein p=the first amino acid of the mature HA.

### Claim 13 (depends on 1)

The influenza hemagglutinin stem domain polypeptide of claim 1, wherein the influenza hemagglutinin stem domain polypeptide does not comprise the intracellular sequence and transmembrane sequence of HA.

### Claim 14 (depends on 13)

The influenza hemagglutinin stem domain polypeptide of claim 13, wherein the influenza hemagglutinin stem domain polypeptide does not comprise the C-terminal part of the influenza H1 HA2 domain spanning from amino acid residue 520, 521, 522, 523, 524, 525, 526, 527, 528, 529 or 530 to the C-terminal amino acid of H1 HA2.

### Claim 15 (depends on 1)

The influenza hemagglutinin stem domain polypeptide of claim 1, wherein the influenza hemagglutinin stem domain polypeptide selectively binds to antibody CR6261 and/or antibody CR9114, but does not bind to antibody CR8057.

### Claim 16 (depends on 1)

The influenza hemagglutinin stem domain polypeptide of claim 1, wherein the influenza hemagglutinin stem domain polypeptide selectively binds to antibody CR8020, antibody CR843 and/or antibody CR9114, but does not bind to antibody CR8057.

### Claim 17

An influenza hemagglutinin stem domain polypeptide produced by a method comprising:
providing an influenza HA0 peptide;
removing the cleavage site between HA1. and HA2 of the influenza HA0 peptide;
removing the peptide of the globular head domain from the HA0 sequence;
introducing one or more mutations in the peptide connecting the C-terminal residue of helix A to the N-terminal residue of helix CD; and
introducing one or more disulfide bridges in the HA stem domain polypeptide.

### Claim 18 (depends on 1)

A nucleic acid molecule encoding the influenza hemagglutinin stem domain polypeptide of claim 1.

### Claim 19 (depends on 1)

An immunogenic composition comprising:
the influenza hemagglutinin stem domain polypeptide of claim 1.

### Claim 20 (depends on 1)

A medicament comprising:
the influenza hemagglutinin stem domain polypeptide of claim 1.

### Claim 21 (depends on 8)

The influenza hemagglutinin stem domain polypeptide of claim 8, wherein the C-terminal amino acid residue of the HA1. C-terminal stem segment is glutamine (Q).
